Cytochroma is a clinical-stage pharmaceutical company established in 1996 that specializes in advanced solutions for chronic kidney disease (CKD) patients dealing with vitamin D insufficiency and hyperphosphatemia. The company's robust portfolio of innovative therapies is tailored to target vitamin D insufficiency and secondary hyperparathyroidism (SHPT) in patients with Stage 3, 4, or 5 CKD. Moreover, Cytochroma is focused on developing new treatments for hyperphosphatemia, aiming to better manage SHPT in individuals with CKD.
The latest notable investment was a $45.00M Series C investment led by a consortium of investors, including Novo Holdings, GrowthWorks Capital, Canadian Medical Discoveries Fund, The VentureLink Innovation Fund, BDC Capital, VenGrowth Asset Management, Mitsubishi Tanabe Pharma, and Caisse de Depot et Placement du Quebec, on 30 July 2008.
Operating within the biotechnology and pharmaceutical industries, Cytochroma is positioned to address critical unmet medical needs in CKD patients, making the company an intriguing prospect for venture capital investment.
